Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 0 0
Stock impact report

Bavarian Nordic Announces Initiation of Clinical Trial Evaluating the Combination Therapy of CV301 and Durvalumab in Metastatic Colorectal and Pancreatic Cancers

BAVARIAN NORDIC R/I S/ADR (BVNRY) 
NASDAQ:AMEX Investor Relations: bavarian-nordic.com/investor.aspx
Company Research Source: GlobeNewswire
Investigator-led study has commenced dosing Immunotherapy candidate CV301 is now being assessed in three clinical trials in combination with checkpoint inhibitors in multiple solid tumors  COPENHAGEN, Denmark, November 2, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced that the first patient has been dosed in a clinical study evaluating CV301, the Company's targeted immunotherapy candidate, and durvalumab, AstraZeneca's PD-L1 inhibitor, in combination with maintenance chemotherapy for patients with metastatic colorectal or pancreatic cancers.  Bavarian Nordic's CV301 targets tumor-associated antigens, CEA and MUC1, which are overexpressed on multiple solid tumors, including colorectal and pancreatic cancers. Preclinical data has shown that vaccination resulted in the induction of tumor specific T-cells that infiltrated the tumor resulting in the upregulation of PD-L1 on tumor cells. The upregulation of PD-L1 is a marker indicating the tumor is under attack f Show less Read more
Impact Snapshot
Event Time:
BVNRY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for BVNRY alerts
Opt-in for
BVNRY alerts

from News Quantified
Opt-in for
BVNRY alerts

from News Quantified